Please wait while the formulary information is being retrieved.
CESAMET (NABILONE)
- Cancer chemotherapy-induced nausea and vomiting
1 mg capsule
- 1 capsule (1 mg) by oral route 2 times per day
Cancer chemotherapy-induced nausea and vomiting
- 1 capsule (1 mg) by oral route 3 times per day
- 1 capsule (1 mg) by oral route 2 times per day
- 1 capsule (1 mg) by oral route 2 times per day (first dose 1 to 3 hours prior to chemotherapy)
- 1 capsule (1 mg) by oral route 3 times per day (first dose 1 to 3 hours prior to chemotherapy)
- 1 capsule (1 mg) by oral route once the night prior to chemotherapy
- 2 capsules (2 mg) by oral route once the night prior to chemotherapy
- 2 capsules (2 mg) by oral route 2 times per day (first dose1 to 3 hours prior to chemotherapy)
- 2 capsules (2 mg) by oral route 3 times per day (first dose1 to 3 hours prior to chemotherapy)
- 2 capsules (2 mg) by oral route 2 times per day
- 2 capsules (2 mg) by oral route 3 times per day
- None
Contraindicated
- None
Severe
Moderate
- None
- Lactating mother
Contraindicated
- Depression
- Manic disorder
- Psychotic disorder
- Schizophrenia
Severe
Moderate
- Cardiac arrhythmia
- Chronic heart failure
- Coronary artery disease
- Drug abuse
- Hypertension
- Hypotension
- Severe hepatic disease
CESAMET (NABILONE)
- Cancer chemotherapy-induced nausea and vomiting
- Hypotension
- Vertigo
- Acute confusion
- Dizziness
- Drowsy
- Dyskinesia
- False sense of well-being
- Headache disorder
- Unsteady gait
- Xerostomia
More Frequent
Severe
Less Severe
- None
- General weakness
- Insomnia
- Nausea
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- Anorexia
- Blurred vision
- Increased appetite
- Muscle weakness
- Myalgias
- Orthostatic hypotension
- Visual changes
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Nabilone
Safety and efficacy not established age <18 years.
- 1 Day – 18 Years
- Safety and efficacy not established age <18 years.
Nabilone
- Severity Level:
C
- Additional Notes: Developmental toxicity seen in animals with chemically similar drugs
Contraindicated
Nabilone
Use not recommended, safety has not been established.
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Use not recommended, safety has not been established. |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Cancer chemotherapy-induced nausea and vomiting | |
| R11.2 | Nausea with vomiting, unspecified |
| Z51.11 | Encounter for antineoplastic chemotherapy |
| 0-9 | A-Z |
|---|---|
| R11.2 | Nausea with vomiting, unspecified |
| Z51.11 | Encounter for antineoplastic chemotherapy |
Formulary Reference Tool